ARTELO BIOSCIENCES, INC. Accrued Liabilities, Current
ARTELO BIOSCIENCES, INC. (ARTL) had Accrued Liabilities, Current of $0 as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-12
- 2026-06-30: Accrued Liabilities, Current $0.00.
- 2026-03-31: Accrued Liabilities, Current $26.00K.
- 2025-12-31: Accrued Liabilities, Current $11.00K.
- 2025-09-30: Accrued Liabilities, Current $46.00K.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-12 |
| 2026-03-31 | $26.00K 10-Q · filed 2026-05-14 |
| 2025-12-31 | $11.00K 10-Q · filed 2026-08-12 |
| 2025-09-30 | $46.00K 10-Q · filed 2025-11-12 |
| 2025-06-30 | $18.00K 10-Q · filed 2025-08-13 |
| 2024-12-31 | $0.00 8-K · filed 2026-03-17 |
| 2017-05-31 | $1.60K 10-Q · filed 2017-07-21 |
| 2017-02-28 | $847.00 10-Q · filed 2017-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B |